{
    "name": "Lycopus",
    "comment": "Herb/Suppl",
    "other_names": [
        "bugleweed",
        "gypsywort",
        "Virginia bugleweed",
        "water horehound",
        "wolfstrappkraut"
    ],
    "classes": [
        "Metabolic & Endocrine",
        "Herbals"
    ],
    "source": "https://reference.medscape.com/drug/bugleweed-gypsywort-lycopus-344526",
    "pregnancy": {
        "common": [
            "Pregnancy Category: avoid",
            "Lactation: avoid"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: avoid"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Pregnancy, lactation",
                "Hypothyroidism"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "May cause hypoglycemia"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "levothyroxine",
            "description": {
                "common": "lycopus decreases effects of levothyroxine by pharmacodynamic antagonism. Contraindicated. Lycopus blocks peripheral conversion of T4 to T3."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "thyroid desiccated",
            "description": {
                "common": "lycopus decreases effects of thyroid desiccated by pharmacodynamic antagonism. Contraindicated. Lycopus blocks peripheral conversion of T4 to T3."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "iodine (radioactive)",
            "description": {
                "common": "lycopus increases effects of iodine (radioactive) by pharmacodynamic synergism. Use Caution/Monitor. Lycopus blocks peripheral conversion of T4 to T3."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methimazole",
            "description": {
                "common": "lycopus increases effects of methimazole by pharmacodynamic synergism. Use Caution/Monitor. Lycopus blocks peripheral conversion of T4 to T3."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "propylthiouracil",
            "description": {
                "common": "lycopus increases effects of propylthiouracil by pharmacodynamic synergism. Use Caution/Monitor. Lycopus blocks peripheral conversion of T4 to T3."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "acarbose",
            "description": {
                "common": "lycopus increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction)."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "chlorpropamide",
            "description": {
                "common": "lycopus increases effects of chlorpropamide by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction)."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "glimepiride",
            "description": {
                "common": "lycopus increases effects of glimepiride by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction)."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "glipizide",
            "description": {
                "common": "lycopus increases effects of glipizide by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction)."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "glyburide",
            "description": {
                "common": "lycopus increases effects of glyburide by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction)."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "insulin aspart",
            "description": {
                "common": "lycopus increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction)."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "insulin detemir",
            "description": {
                "common": "lycopus increases effects of insulin detemir by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction)."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "insulin glargine",
            "description": {
                "common": "lycopus increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction)."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "insulin glulisine",
            "description": {
                "common": "lycopus increases effects of insulin glulisine by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction)."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "insulin lispro",
            "description": {
                "common": "lycopus increases effects of insulin lispro by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction)."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "insulin NPH",
            "description": {
                "common": "lycopus increases effects of insulin NPH by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction)."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "insulin regular human",
            "description": {
                "common": "lycopus increases effects of insulin regular human by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction)."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "metformin",
            "description": {
                "common": "lycopus increases effects of metformin by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction)."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "miglitol",
            "description": {
                "common": "lycopus increases effects of miglitol by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction)."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nateglinide",
            "description": {
                "common": "lycopus increases effects of nateglinide by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction)."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "pioglitazone",
            "description": {
                "common": "lycopus increases effects of pioglitazone by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction)."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "repaglinide",
            "description": {
                "common": "lycopus increases effects of repaglinide by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction)."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "rosiglitazone",
            "description": {
                "common": "lycopus increases effects of rosiglitazone by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction)."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "saxagliptin",
            "description": {
                "common": "lycopus increases effects of saxagliptin by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction)."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "sitagliptin",
            "description": {
                "common": "lycopus increases effects of sitagliptin by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction)."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tolazamide",
            "description": {
                "common": "lycopus increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction)."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tolbutamide",
            "description": {
                "common": "lycopus increases effects of tolbutamide by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction)."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "vildagliptin",
            "description": {
                "common": "lycopus increases effects of vildagliptin by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction)."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "None in regular doses",
            "percent": null
        }
    ]
}